Literature DB >> 19875392

Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?

N Pandeya1, P M Webb, S Sadeghi, A C Green, D C Whiteman.   

Abstract

OBJECTIVE: To measure the extent to which risks of oesophageal cancers associated with gastro-oesophageal reflux (GOR) are modified by common factors including smoking, non-steroidal anti-inflammatory drugs (NSAIDs) and acid suppressant medications. DESIGN AND
SETTING: Population-based case-control study. PARTICIPANTS: Cases were patients with oesophageal (OAC; n = 365) or gastro-oesophageal junction (GOJAC; n = 426) adenocarcinomas, or squamous cell carcinomas (OSCC; n = 303). Controls were sampled from a population register (n = 1580). MAIN OUTCOME MEASURE: Odds ratio and 95% confidence interval.
RESULTS: Frequent (at least weekly) symptoms of GOR were associated with significant 6.4-fold, 4.6-fold and 2.2-fold increased risks of OAC, GOJAC and OSCC, respectively. Under models examining effects of combined exposure, patients with frequent GOR symptoms who were also heavy smokers had markedly higher OAC risks (OR = 12.3, 95% CI 6.3 to 24.0) than those with frequent GOR who did not smoke (OR = 6.8, 95% CI 3.6 to 12.9). Similar patterns were observed for GOJAC and OSCC. Among people with frequent GOR symptoms, regular use of aspirin/NSAIDs was associated with almost two-thirds lower OAC risks (OR = 4.8, 95% CI 2.5 to 9.2) than non-users (13.9, 95% CI 6.5 to 30.0). In contrast, among those with frequent GOR symptoms, users of acid suppressants had similar OAC risks (OR 7.8, 95% CI 5.2 to 11.8) to non-users (OR 5.3, 95% CI 3.2 to 9.0).
CONCLUSIONS: People experiencing frequent GOR symptoms have markedly increased risks of OAC and GOJAC, and this effect may be greater amongst smokers. Use of aspirin and NSAIDs, but not acid suppressants, significantly reduced the risks of oesophageal cancers associated with GOR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19875392     DOI: 10.1136/gut.2009.190827

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

Review 1.  Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.

Authors:  Jacquelyn S Carr; Syed F Zafar; Nabil Saba; Fadlo R Khuri; Bassel F El-Rayes
Journal:  J Gastrointest Cancer       Date:  2013-06

2.  Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium.

Authors:  Michael B Cook; Nicholas J Shaheen; Lesley A Anderson; Carol Giffen; Wong-Ho Chow; Thomas L Vaughan; David C Whiteman; Douglas A Corley
Journal:  Gastroenterology       Date:  2012-01-11       Impact factor: 22.682

3.  Upper gastrointestinal cancer in its early stages is predominantly asymptomatic.

Authors:  James W Berrill; Jeff K Turner; Jo J Hurley; Gillian Swift; Sunil Dolwani; John T Green
Journal:  Frontline Gastroenterol       Date:  2011-09-10

4.  Esophageal malignancy: a growing concern.

Authors:  Jianyuan Chai; M Mazen Jamal
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 5.  Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?

Authors:  Sebastian F Schoppmann; Ivan Kristo; Martin Riegler
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-05

6.  Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells.

Authors:  Kuancan Liu; Ming Jiang; Yun Lu; Hao Chen; Jun Sun; Shaoping Wu; Wei-Yao Ku; Hiroshi Nakagawa; Yoshiaki Kita; Shoji Natsugoe; Jeffrey H Peters; Anil Rustgi; Mark W Onaitis; Amy Kiernan; Xiaoxin Chen; Jianwen Que
Journal:  Cell Stem Cell       Date:  2013-03-07       Impact factor: 24.633

Review 7.  Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease.

Authors:  Matthew F Buas; Thomas L Vaughan
Journal:  Semin Radiat Oncol       Date:  2013-01       Impact factor: 5.934

8.  Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.

Authors:  Ravinder Kodela; Mitali Chattopadhyay; Satindra Goswami; Zong Yuan Gan; Praveen P N Rao; Kamran V Nia; Carlos A Velázquez-Martínez; Khosrow Kashfi
Journal:  J Pharmacol Exp Ther       Date:  2013-01-24       Impact factor: 4.030

9.  Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study.

Authors:  Sc Cooper; S Menon; Pg Nightingale; Nj Trudgill
Journal:  United European Gastroenterol J       Date:  2014-04       Impact factor: 4.623

10.  Age at onset of GERD symptoms predicts risk of Barrett's esophagus.

Authors:  Aaron P Thrift; Jennifer R Kramer; Zeeshan Qureshi; Peter A Richardson; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2013-04-09       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.